

FIVE-YEAR SURVIVAL IS SIMILAR IN THYROID CANCER PATIENTS WITH DISTANT METASTASES PREPARED FOR RADIOACTIVE IODINE THERAPY WITH EITHER THYROID HORMONE WITHDRAWAL OR RECOMBINANT HUMAN THYROTROPIN

Tala H, et. al.

disease possibly will not result in the same results as achieved at this premier institution for thyroid cancer care. I cannot conclude that patients with iodine-avid distant disease will be adequately treated with rhTSH and empirical doses of RAI, but it is fair to say that a four-dose rhTSH-stimulated dosimetry-

determined treatment with RAI for a patient with RAI-avid metastatic disease appears to be a reasonable alternative to traditional thyroid hormone withdrawal RAI treatments.

— **Stephanie L. Lee, MD, PhD**

References

1. Elisei R, Schlumberger M, Driedger A, Reiners C, Kloos RT, Sherman SI, Haugen B, Corone C, Molinaro E, Grasso L, Leboulleux S, Rachinsky I, Luster M, Lassmann M, Busaidy NL, Wahl RL, Pacini F, Cho SY, Magner J, Pinchera A, Ladenson PW. Follow-up of low-risk differentiated thyroid cancer patients who underwent radioiodine ablation of postsurgical thyroid remnants after either recombinant human thyrotropin or thyroid hormone withdrawal. *J Clin Endocrinol Metab* 2009;94:4171-9. Epub October 22, 2009.
2. Pilli T, Brianzoni E, Capocchetti F, Castagna MG, Fattori S, Poggiu A, Rossi G, Ferretti F, Guarino E, Burrioni L, Vattimo A, Cipri C, Pacini F. A comparison of 1850 (50 mCi) and 3700 MBq (100 mCi) ¹³¹-iodine administered doses for recombinant thyrotropin-stimulated postoperative thyroid remnant ablation in differentiated thyroid cancer. *J Clin Endocrinol Metab* 2007;92:3542-6.
3. Tuttle RM, Lopez N, Leboeuf R, Minkowitz SM, Grewal R, Brokhin M, Omry G, Larson S. Radioactive iodine administered for thyroid remnant ablation following recombinant human thyroid stimulating hormone preparation also has an important adjuvant therapy function. *Thyroid* 2010;20:257-63.
4. Luster M, Lippi F, Jarzab B, Perros P, Lassmann M, Reiners C, Pacini F. rhTSH-aided radioiodine ablation and treatment of differentiated thyroid carcinoma: a comprehensive review. *Endocr Relat Cancer* 2005;12:49-64.